TICKERNERD
Menu
OPKOPKHealthcare · Diagnostics & Research

OPK Stock Forecast: OPKO Health, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$1.64
−3.53% on the day

The 6 Wall Street analysts covering OPKO Health, Inc. hold a median 12-month price target of $3 — +82.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 23 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.3B
Ticker Nerd rank
82 / 100
Median analyst target
$3.00
Analysts covering
6
Revenue$163.6M+4.3% y/y
Operating income−$25.0M
Net income−$8.4M
Free cash flow−$46.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.2%
1M
+10.8%
YTD
+30.2%
1Y
+10.8%
From 52W high
−5.2%
From 52W low
+49.1%
$1.10
$1.73
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OPK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OPKO Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
90
Revisions
89
Issuance
77
Volatility
74
Momentum
69
Accruals
57
Quality
45
Size
41
Value
29

Growth (90): Sales and profits are climbing, and climbing faster than before.

Value (29): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OPK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OPK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26OPKHigh $8.50Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
4 Buy2 Hold0 Sell
Low $3.00Median $3.00High $8.50

The green dot is the last close — the median target sits +82.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Apr 2026Barrington ResearchDowngradeMarket Perform—
2 Mar 2026Barrington ResearchMaintainsOutperform—
20 Nov 2025JP MorganInitiatesNeutral—
31 Oct 2025JefferiesDowngradeHold—
30 Oct 2025Barrington ResearchMaintainsOutperform—
1 May 2025Barrington ResearchMaintainsOutperform—
25 Apr 2025JP MorganInitiatesNeutral—
7 Apr 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025Barrington ResearchMaintainsOutperform—
12 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Feb 2025Barrington ResearchMaintainsOutperform—
8 Jan 2025HC Wainwright & Co.MaintainsBuy—
8 Nov 2024Barrington ResearchMaintainsOutperform—
26 Sept 2024HC Wainwright & Co.ReiteratesBuy—
20 Sept 2024Barrington ResearchMaintainsOutperform—
17 Sept 2024HC Wainwright & Co.ReiteratesBuy—
17 Sept 2024Piper SandlerReiteratesOverweight—
8 Aug 2024Barrington ResearchMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OPK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, OPKO Health, Inc. returned +10.8% against +17.3% for the S&P 500, dividends included.

OPK vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Oct 25Jan 26Apr 26Jul 26OPKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OPK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

OPKO Health, Inc. (OPK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.5×

Cheaper than 90% of US stocks

Price / sales
2.2×

Cheaper than 51% of US stocks

Price / book
1.1×

Cheaper than 71% of US stocks

EV / EBITDA
−17.5×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
4.3%

Higher than 37% of US stocks

Earnings growth (YoY)
4.3%

Higher than 41% of US stocks

Gross margin
48.9%

Higher than 61% of US stocks

Operating margin
−15.3%

Higher than 23% of US stocks

Net margin
−12.4%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−5.9%

Higher than 38% of US stocks

Return on assets
−5.5%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

OPKO Health, Inc. (OPK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • OPKO Health, Inc. has a market value of $1.3B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $587.9M. The latest quarter grew 4.3% year on year.

  • Net income over the same four quarters: −$72.9M, a −12.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.09.

  • Free cash flow in the twelve months to 30 June 2026: −$134.0M, after $10.6M of capital spending.

  • OPKO Health, Inc. spent $46.6M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 746.0M.

  • Trailing P/E: −5.5×; forward P/E: −6.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • OPKO Health, Inc. employs 2,275 people — $258K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

OPK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
OPKOPKO Health, Inc.$1.3B
82
CSTLCastle Biosciences, Inc.$1.0B
87
PSNLPersonalis, Inc.$1.7B
42
FRNMFreenome, Inc.$1.7B
32
NEONeoGenomics, Inc.$2.4B
77
WGSGeneDx Holdings Corp.$2.4B
46
FLGTFulgent Genetics, Inc.$604.1M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OPKO Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OPK news & analysis

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

Zacks Investment Research · 21 Sept 2026positive

OPKO Health's stock has risen 32.5% year-to-date in 2026, with the rally attributed to pharmaceutical growth, a broad clinical pipeline, strategic partnerships, and new non-dilutive financing.

Why it matters — A OPK watcher would care because these factors—pipeline, partnerships, and non-dilutive financing—are central drivers shaping the company's performance and share-price momentum this year.

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

MarketBeat · 11 Sept 2026positive

OPKO Health outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations. Management highlighted a pipeline of early-stage clinical programs, external collaborations, and available capital to fund development over a data-rich 12-to-18-month period.

Why it matters — OPK watchers would care because the company's strategic pivot toward therapeutics and its development pipeline could shape its future business mix and direction.

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

GlobeNewsWire · 8 Sept 2026neutral

OPKO Health, Inc. announced it will participate in the Wells Fargo 21st Annual Healthcare Conference. The announcement was made via press release on September 8, 2026, from Miami.

Why it matters — OPK watchers would care because the company's participation indicates it will present or engage with investors at a major healthcare industry conference.

Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

Zacks Investment Research · 26 Aug 2026negative

OPKO Health (OPK) reported earnings 30 days ago, and its stock is down 9.7% since that earnings report. The item notes that the company's next move for the stock is being watched.

Why it matters — An OPK watcher would care because the stock has declined notably in the month following the latest earnings report, with attention now on what comes next for the company.

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research advises investors to retain OPKO Health stock, citing a growth outlook supported by RAYALDEE, strategic partnerships, BioReference restructuring, and multiple pipeline catalysts.

Why it matters — OPK watchers would care because the report highlights the company's current product, partnerships, restructuring, and pipeline as factors supporting its outlook.

FAQ

Frequently asked questions about OPK stock

What is the OPK stock price forecast for 2026-2027?

The 6 Wall Street analysts covering OPKO Health, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $8.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OPK stock a buy right now?

Of the 6 analysts covering OPKO Health, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OPKO Health, Inc. 82 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OPK?

As at 23 Sept 2026, OPKO Health, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).

Will OPK stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +82.9% from the last close, and Ticker Nerd's factor model ranks OPKO Health, Inc. 82 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OPK stock forecast for 2030?

No analyst covering OPKO Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $8.5 over the next 12 months.

How has OPK stock performed over the past year?

OPKO Health, Inc. returned +10.8% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OPKO Health, Inc. do?

OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals.

What is the latest news on OPK?

The most recent item we track (Zacks Investment Research, 21 Sept 2026): "OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?". OPKO Health's stock has risen 32.5% year-to-date in 2026, with the rally attributed to pharmaceutical growth, a broad clinical pipeline, strategic partnerships, and new non-dilutive financing.

Company

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals. Through its Diagnostics segment, the company provides clinical laboratory and genetic testing services, including BioReference Health and specialized assays used in disease detection, monitoring, and patient management. Its Pharmaceutical segment markets approved therapies and supports development programs across areas such as kidney disease, hormone-related disorders, oncology, and infectious diseases. OPKO Health also works with commercial partners and maintains manufacturing, supply, and research activities across several international markets. The company plays a broad role in the healthcare market by combining testing services, marketed medicines, and pipeline assets within a single operating platform. OPKO Health, Inc. is headquartered in Miami, Florida.

CEO Dr. Phillip Frost M.D., Ph.D. · 2,275 employees · United States · https://www.opko.com